Uptake of Statin Guidelines to Prevent and Treat Cardiovascular Disease

References

1. 1.↵
   1. Mensah GA,
   2. Brown DW

   . An overview of cardiovascular disease burden in the United States. Health Aff (Millwood) 2007;26:38–48.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Chou R,
   2. Dana T,
   3. Blazina I,
   4. Daeges M,
   5. Jeanne TL

   . Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;316:2008–24.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Mortensen MB,
   2. Nordestgaard BG

   . Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat. JAMA Cardiol 2019;4:1131–8.

   OpenUrl
4. 4.↵
   1. Stone NJ,
   2. Robinson J,
   3. Lichtenstein AH,
   4. et al

   . 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1–S45.

   OpenUrlFREE Full Text
5. 5.↵
   National Cholesterol Education Program. ATP III guidelines at-a-glance: quick desk reference. 2004. Available from: https://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf. Accessed February 24, 2020.
6. 6.↵
   1. Rabar S,
   2. Harker M,
   3. O’Flynn N,
   4. Wierzbicki AS

   . Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014;349:g4356.

   OpenUrlFREE Full Text
7. 7.↵
   1. Ray KK,
   2. Kastelein JJP,
   3. Boekholdt SM,
   4. et al

   . The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960–8.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Bibbins-Domingo K,
   2. Grossman DC,
   3. Curry SJ,
   4. et al

   . Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA 2016;316:1997–2007.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Chou R,
   2. Dana T,
   3. Blazina I,
   4. et al

   . Statin use for the prevention of cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016.
10. 10.↵
    1. Pencina MJ,
    2. Navar-Boggan AM,
    3. D’Agostino Sr RB,
    4. et al

    . Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422–31.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Pokharel Y,
    2. Tang F,
    3. Jones PG,
    4. et al

    . Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management guideline in cardiology practices nationwide. JAMA Cardiol 2017;2:361–9.

    OpenUrl
12. 12.↵
    1. Bellows BK,
    2. Olsen CJ,
    3. Voelker J,
    4. Wander C

    . Antihyperlipidemic medication treatment patterns and statin adherence among patients with ASCVD in a managed care plan after release of the 2013 ACC/AHA guideline on the treatment of blood cholesterol. J Manag Care Spec Pharm 2016;22:892–900.

    OpenUrl
13. 13.↵
    1. Rodriguez F,
    2. Lin S,
    3. Maron DJ,
    4. Knowles JW,
    5. Virani SS,
    6. Heidenreich PA

    . Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: practice impact of the new cholesterol guidelines. Am Heart J 2016;182:97–102.

    OpenUrl
14. 14.↵
    1. Harrison TN,
    2. Scott RD,
    3. Cheetham TC,
    4. et al

    . Trends in statin use 2009–2015 in a large integrated health system: pre- and post-2013 ACC/AHA guideline on treatment of blood cholesterol. Cardiovasc Drug Ther 2018;32:397–404.

    OpenUrl
15. 15.↵
    1. Tran JN,
    2. Kao TC,
    3. Caglar T,
    4. et al

    . Impact of the 2013 cholesterol guideline on patterns of lipid-lowering treatment in patients with atherosclerotic cardiovascular disease or diabetes after 1 year. J Manag Care Spec Pharm 2016;22:901–8.

    OpenUrl
16. 16.↵
    1. Virani SS,
    2. Pokharel Y,
    3. Steinberg L,
    4. et al

    . Provider understanding of the 2013 ACC/AHA cholesterol guideline. J Clin Lipidol 2016;10:497–504.e494.

    OpenUrlPubMed
17. 17.↵
    1. Ngo-Metzger Q,
    2. Zuvekas SH,
    3. Bierman AS

    . Estimated impact of US Preventive Services Task Force recommendations on use and cost of statins for cardiovascular disease prevention. J Gen Intern Med 2018;33:1317–23.

    OpenUrl
18. 18.↵
    1. Grundy SM,
    2. Stone NJ,
    3. Bailey AL,
    4. et al

    . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2019;73:e285–e350.

    OpenUrlFREE Full Text
19. 19.↵
    1. Krist AH,
    2. Aycock RA,
    3. Etz RS,
    4. et al

    . MyPreventiveCare: implementation and dissemination of an interactive preventive health record in three practice-based research networks serving disadvantaged patients-a randomized cluster trial. Implement Sci 2014;9:181.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Ryan GW,
    2. Bernard HR

    . Techniques to identify themes. Field Methods 2003;15:85–109.

    OpenUrlCrossRef
21. 21.↵
    1. Adler NE,
    2. Cutler DM,
    3. Fielding JE,
    4. et al

    . Addressing social determinants of health and health disparities: A vital direction for health and health care. NAM Perspectives. Discussion Paper, National Academy of Medicine. Washington, DC; 2016.